Free · no account · quoted from the filing

What changed in BDX's 10-Q

Source: 10-Q filed 2026-05-07 · compared against 10-Q 2026-02-09. Every passage below is quoted verbatim from the filing itself.

Spin-off and Discontinued Operations

This filing

Spin-off of Biosciences and Diagnostic Solutions business

Profitability

This filing

Net (Loss) Income $ (311)

Revenue Growth

This filing

worldwide revenues of $4.714 billion increased 5.2%

Risk Factors

This filing

The ongoing conflict in Iran and the Middle East region has not yet significantly impacted our global supply chain

Capital Allocation

This filing

paid cash to repurchase approximately $2.250 billion of our common stock

Medical Essentials Segment

This filing

Lower gross profit margin in the second quarter

What it means — the analyst reading

The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel — is part of the Filing Change Monitor.

See the Filing Change Monitor →

Compared from narrative excerpts (outlook, risks, MD&A) of both filings — quotes are verbatim from the new filing. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.